15 results about "Glucose stimulation" patented technology

The invention relates to the technical field of biology, in particular to application of SAFit2 in preparation of a reagent for improving pancreas islet dysfunction. The invention discovers that SAFit2 has a remarkable improvement effect on insulin secretion dysfunction in a high-glucose and high-fat induced islet injury model. Experiments show that in a high glucose (33 mM) combined palmitic acid (500 [mu] M) injury model, the SAFit2 can significantly improve the insulin secretion function of the pancreas islet. Specifically, the SAFit2 is pretreated, the glucose stimulated insulin secretion (GSIS) index of the pancreas islet and the intracellular insulin content are remarkably increased, insulin secretion under high glucose stimulation is promoted, and the SAFit2 is proved to have the effect of promoting the insulin secretion function of the pancreas islet beta cells.

The invention relates to the technical field of biological medicines, in particular to a miR-23a-5p cavernous body, a cavernous adeno-associated virus, a preparation method of the miR-23a-5p cavernous body and the cavernous adeno-associated virus and application of the miR-23a-5p cavernous body and the cavernous The invention provides a miR-23a-5p cavernous body, and the nucleotide sequence of the miR-23a-5p cavernous body is as shown in SEQ ID NO. 1. The miR-23a-5p cavernous body and the miR-23a-5p cavernous adeno-associated virus prepared from the miR-23a-5p cavernous body can effectively relieve insulin secretion function damage caused by islet glucose stimulation and peripheral tissue insulin resistance caused by high-fat feeding, and can be used as a miR-23a-5p inhibitor to inhibit miR-23a-5p expression in adipose tissues, improve insulin resistance and inhibit the growth of the adipose tissues. And occurrence and development of type 2 diabetes mellitus are controlled.

Provided are preparation methods for an islet extracellular matrix scaffold and a biomimetic islet organoid. The scaffold is a gel, and the gel contains 3-5 mg / mL Collagen I, 3-5 mg / mL Collagen IV, and 0.8-1.2 mg / mL Laminin. For the scaffold, Collagen I, Collagen IV, and Laminin are simultaneously selected as extracellular matrix components, which have relatively strong interactions with islet cells, and effectively promote the islet cells and enhance insulin secretion function stimulated by glucose after binding to the islet cells. Collagen VI can also be used. Collagen VI can act on the islet cells to effectively enhance the survival of the islet cells and the insulin secretion function stimulated by glucose. The gel can form a relatively intact network structure without needing to use a cross-linking agent, thereby enhancing the support capacity for the islet organoid.

The invention relates to the field of biology, in particular to application of tauroursodeoxycholic acid in preparation of a medicine for promoting function maturation of islet organs. The specific effect of tauroursodeoxycholic acid in promoting functional maturation of iPSC-derived islet-like organs is found and verified for the first time, and a brand new treatment thought is represented. The beta cell functional gene expression and glucose stimulation response capability of the sc-islet can be remarkably improved only by performing TUDCA treatment for 96 hours, and the function maturation period is greatly shortened. The obvious effect can be achieved by adopting the low-dose TUDCA with the concentration of 25-100 ng / mL, the cost is reduced, and the potential toxicity risk is reduced. Key indexes (functional gene expression and glucose response) of beta cell maturation are directly targeted, and a high-quality cell model is provided for research and treatment of diabetes mellitus.

The present application provides a kind of active glycopeptide of Hericium erinaceus with liver protection, blood sugar reduction and immune activity and its preparation method and application, belong to edible fungus processing technical field.The present application provides an active glycopeptide of Hericium erinaceus, the amino acid sequence of the active glycopeptide of Hericium erinaceus is as shown in SEQ ID NO:1;The Thr site of the active glycopeptide of Hericium erinaceus is connected by O-connection mode with the oligosaccharide chain consisting of 7 mannose residues.The active glycopeptide of Hericium erinaceus of the present application can promote cell consumption glucose, stimulate macrophage cell production NO, and can relieve hydrogen peroxide induced liver injury.Animal model experiment of the present application shows that the active glycopeptide of Hericium erinaceus can effectively reduce fasting blood sugar level, regulate the tolerance of organism to glucose, and can relieve liver inflammatory response, improve fat metabolism in liver.

The invention belongs to the technical field of drug synthesis, and relates to a quinolinone derivative which is a compound with a structure shown in a general formula (I) and an isomer or pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof, and is used for preparing drugs for treating and / or preventing diabetes-related diseases. The compound plays a role by promoting glucose consumption of an organism, and can promote glucose consumption of HepG2 hepatocytes and 3T3-L1 adipocytes in vitro; in an in-vivo experiment, after intragastric administration of the compound, the blood glucose level of a normal C57BL / 6j mouse after glucose stimulation is reduced in a dose-dependent manner; the fasting blood glucose, the random blood glucose, the food intake and the water intake of db / db diabetes model mice are reduced in a dose-dependent manner, the glucose tolerance of the db / db mice is improved, and the protective effect on the liver function is displayed.

A method to enhance beta-islet function and survival for treatments of diabetes by targeting PRKAR2B, and a method of preparing genetically modified human pluripotent stem cell (hPSC) in vitro, comprising providing hPSCs, with said modification comprising reducing or eliminating the expression or function of the gene products of the PRKAR2B gene in said hPSCs to be capable of differentiating in vitro to give rise to beta islets with enhanced function in glucose-stimulated insulin secretion and cell survival,are provided.

The invention relates to the technical field of regenerative medicine and cell therapy, in particular to a culture medium for inducing mesenchymal cells to differentiate into insulin-secreting cells and application of the culture medium. By accurately regulating and controlling the oxidation-reduction state of NAD < + > / NADH in cells, the composition proportion of exogenous fatty acid, the dynamic supply concentration of glucose and the anti-oxidative stress level, the differentiation efficiency is remarkably improved, the induction period is shortened, and the method is suitable for industrial production on the premise of not depending on recombinant protein induction factors such as Activin A and Wnt3a. And a mature beta-like cell with stable glucose stimulus dependent insulin secretion (GSIS) capability is obtained. The kit is especially suitable for human adipose tissue-derived mesenchymal stem cells, and can be used as an independent kit product for preclinical research and drug screening of diabetes cell replacement therapy.

The application relates to the technical field of biological pharmacy, in particular to application of recombinant protein DEL-1 in preparation of a drug for improving insulin secretion function of human islets. The application finds that the recombinant protein DEL-1 has a significant improvement effect on insulin secretion dysfunction in various human islet injury models. Experiments show that in a high-sugar combined palmitic acid injury model and an inflammatory cytokine injury model, DEL-1 can significantly improve the insulin secretion function of human islets. Specifically, compared with an injury group, after DEL-1 treatment, the glucose stimulation index of human islets and the relative secretion amount of insulin under high-sugar stimulation are both significantly increased, which proves that DEL-1 has a clear effect of promoting insulin secretion function of human islet beta cells.

The invention relates to the field of cell culture, and discloses a pancreatic islet organ and a culture method thereof, the method realizes differentiation of human induced pluripotent stem cells to functional pancreatic islet organs through sequential stage conversion, and the method comprises the following steps: in a two-dimensional culture stage, pancreatic progenitor cells are induced by adopting a specific factor combination; in the three-dimensional maturation stage, the cells are promoted to be self-assembled into a pancreas islet-like structure through a suspension culture technology. The diameter of the cultured islet organ is 100-200 [mu] m, the islet organ contains alpha, beta and delta cells, the proportion of the alpha, beta and delta cells is close to that of natural islet, and the insulin secretion amount under the stimulation of 16.7 mM glucose reaches 2.5 times or above of the basic level. According to the invention, the serum-free chemically defined culture medium is adopted to replace animal source components, and an optimized suspension culture process is combined, so that the technical problems of nonuniform size, insufficient functional activity, strong matrigel dependence and the like of organoids in a traditional method are solved, and a standardized and large-scale cell source is provided for diabetes treatment.

The invention relates to the technical field of regenerative medicine and cell therapy, in particular to a method for inducing mesenchymal stem cells to differentiate into insulin-secreting cells and application of the method. According to the method, a culture system is regulated and controlled by stages, the glucose concentration is respectively regulated in different induction stages, an NAD + precursor substance, a fatty acid composition and an antioxidant factor are added, and a three-dimensional microcarrier culture mode is combined, so that the cell metabolism state, the oxidation-reduction balance and the space structure are dynamically regulated and controlled. Under the condition of not depending on recombinant protein inducing factors such as Activin A and Wnt3a, the efficient directional differentiation of the mesenchymal stem cells to the insulin-secreting cells is realized. By adopting the method disclosed by the invention, the differentiation efficiency can be improved, the induction period can be shortened, the mature beta-like cells with a stable glucose stimulation dependent insulin secretion function can be obtained, and the method is suitable for induced differentiation and related research application of the human adipose-derived mesenchymal stem cells.

The invention relates to the technical field of biology, and particularly discloses application of deferoxamine and deferiprone in preparation of a biological agent for relieving or preventing hypoxia injury in pancreas islet in-vitro culture. Through combined treatment of deferoxamine and deferoxone, the accumulation amount of Fe < 2 + > and the accumulation amount of a lipid peroxidation product 4-HNE of in-vitro cultured pancreas islet are remarkably reduced, the situation that insulin secretion GSIS is remarkably weakened due to glucose stimulation is remarkably improved, and finally hypoxia injury is reduced.

The invention provides an application of prolactin as an additive for culturing pancreas islet organs. The invention also provides a pancreas islet organ culture medium, which comprises a basic culture medium and prolactin with the concentration of 25-100 ng / mL. The invention also provides a preparation method of the pancreas islet organoid, which is characterized in that pancreas islet precursor cells are differentiated into the pancreas islet organoid in the pancreas islet organoid culture medium. The method is simple to operate, and the pancreas islet organ can be formed only by adding prolactin into a conventional culture medium. The islet organ prepared by the invention has low immunogenicity and an insulin secretion function under glucose stimulation, can normally perform a blood sugar regulation function, and can be used for treating diabetes mellitus.

The subject of the present invention is a use of SPARC / osteonectin, CWCV and a Kazal-like domain proteoglycan-2 (SPOCK2) as a regulator of differentiation of human pluripotent stem cells (hPSCs) towards pancreatic β-cells. SPOCK2 influences the formation of β-cells in a process of differentiation from human stem cells (SC-β, stem cell-derived β-cells), regulating the proliferation and functionality thereof. SPOCK2 is a negative regulator of these processes. Decreasing the level of SPOCK2 contributes to a substantial increase in the proliferation of the SC-β-cells, while activation of SP0CK2 inhibits their expansion. Additionally, the lack of SPOCK2 during the differentiation of hPSCs towards β-cells already at their progenitor step accelerates this process, which results in a more efficient differentiation thereof. The SC-p-cells formed in this manner are characterized by an increased glucose-stimulated in vitro and in vivo insulin (INS) secretion, comparable to human pancreatic islet β-cells. Use of SPOCK2 as a regulator of differentiation of human pluripotent stem cells towards pancreatic β-cells.

The invention relates to the technical field of biopharmacy, in particular to application of recombinant protein DEL-1 in preparation of a medicine for improving a human islet insulin secretion function. The invention discovers that the recombinant protein DEL-1 has a remarkable improvement effect on insulin secretion dysfunction in various human islet injury models. Experiments show that in a high glucose combined palmitic acid damage model and an inflammatory cytokine damage model, the DEL-1 can significantly improve the insulin secretion function of the human pancreas islet. Specifically, compared with an injured group, after DEL-1 treatment, the glucose stimulation index of the human pancreas islet and the relative secretion amount of insulin under high glucose stimulation are remarkably increased, and it is proved that DEL-1 has the definite effect of promoting the insulin secretion function of the human pancreas islet beta cells.